PE20240066A1 - Antibioticos macrociclicos de amplio espectro - Google Patents
Antibioticos macrociclicos de amplio espectroInfo
- Publication number
- PE20240066A1 PE20240066A1 PE2023002563A PE2023002563A PE20240066A1 PE 20240066 A1 PE20240066 A1 PE 20240066A1 PE 2023002563 A PE2023002563 A PE 2023002563A PE 2023002563 A PE2023002563 A PE 2023002563A PE 20240066 A1 PE20240066 A1 PE 20240066A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- compound
- broad spectrum
- methyl
- macrocyclic antibiotics
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto o una sal farmaceuticamente aceptable del mismo; este compuesto es antibioticos macrociclicos de amplio espectro. En donde un compuesto seleccionado es acido (8S,11S,14S)-18-hidroxi-11-metil-14-[metil-[(2S)-2-[[4-amino-2-(4-terc-butilfenil)-6-metil-pirimidin-5-carbonil]amino]-3-(sulfamoilamino)propanoil]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hidroxi-propoxi]-9,12-diazatriciclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaeno-8-carboxilico. Tambien se refiere a metodos para preparar dichos compuestos, una composicion farmaceutica que comprende dicho compuesto y su uso en el tratamiento de infecciones bacterianas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853457P | 2019-05-28 | 2019-05-28 | |
PCT/US2020/034670 WO2020243155A1 (en) | 2019-05-28 | 2020-05-27 | Macrocyclic broad spectrum antibiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240066A1 true PE20240066A1 (es) | 2024-01-11 |
Family
ID=73551292
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023002563A PE20240066A1 (es) | 2019-05-28 | 2020-05-27 | Antibioticos macrociclicos de amplio espectro |
PE2021001977A PE20230383A1 (es) | 2019-05-28 | 2020-05-27 | Antibioticos macrociclicos de amplio espectro |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021001977A PE20230383A1 (es) | 2019-05-28 | 2020-05-27 | Antibioticos macrociclicos de amplio espectro |
Country Status (31)
Country | Link |
---|---|
US (2) | US11208387B2 (es) |
EP (2) | EP4289480A3 (es) |
JP (2) | JP7078807B2 (es) |
KR (2) | KR20220137165A (es) |
CN (2) | CN114007605B (es) |
AR (1) | AR119019A1 (es) |
AU (2) | AU2020282975B2 (es) |
BR (1) | BR112021024010A2 (es) |
CA (1) | CA3141853A1 (es) |
CL (1) | CL2021003153A1 (es) |
CO (1) | CO2021017561A2 (es) |
CR (1) | CR20210682A (es) |
DK (1) | DK3968983T3 (es) |
ES (1) | ES2961566T3 (es) |
FI (1) | FI3968983T3 (es) |
HR (1) | HRP20231497T1 (es) |
HU (1) | HUE063847T2 (es) |
IL (2) | IL288294B (es) |
LT (1) | LT3968983T (es) |
MA (1) | MA55981B1 (es) |
MX (1) | MX2021014554A (es) |
NZ (1) | NZ783605A (es) |
PE (2) | PE20240066A1 (es) |
PL (1) | PL3968983T3 (es) |
PT (1) | PT3968983T (es) |
RS (1) | RS64852B1 (es) |
SA (1) | SA521430976B1 (es) |
SG (1) | SG11202112920SA (es) |
SI (1) | SI3968983T1 (es) |
TW (2) | TWI815017B (es) |
WO (1) | WO2020243155A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016357926B2 (en) | 2015-11-20 | 2021-05-27 | Genentech, Inc. | Macrocyclic broad spectrum antibiotics |
KR102602837B1 (ko) * | 2021-03-08 | 2023-11-15 | 차의과학대학교 산학협력단 | 항독력활성을 가지는 화합물 |
CN113583003A (zh) * | 2021-08-05 | 2021-11-02 | 广东西捷药业有限公司 | 一种伐地那非类似物及其合成方法和应用 |
CN113933416B (zh) * | 2021-09-30 | 2023-10-10 | 海南海灵化学制药有限公司 | 一种注射用硫酸头孢匹罗中杂质的检测方法 |
WO2024102404A1 (en) | 2022-11-11 | 2024-05-16 | Genentech, Inc. | Enzymatic asymmetric syntheses of n-alkyl amino acids |
CN117946013B (zh) * | 2024-01-25 | 2024-07-02 | 白银康寓信生物科技有限公司 | 一锅法合成5,6-二卤代-3-氨基吡嗪-2-甲酸甲酯的方法 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3128280A (en) | 1959-10-23 | 1964-04-07 | Searle & Co | 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas |
US5204328A (en) | 1990-06-26 | 1993-04-20 | Merck & Co., Inc. | Peptides having atrial natriuretic factor activity |
WO1997016558A1 (en) | 1995-11-03 | 1997-05-09 | E.I. Du Pont De Nemours And Company | Positive selection vector for bacillus sp. |
UA66767C2 (uk) | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
EP0895999A1 (en) | 1997-08-06 | 1999-02-10 | Pfizer Products Inc. | C-4" substituted macrolide antibiotics |
GB9902399D0 (en) | 1999-02-03 | 1999-03-24 | Smithkline Beecham Plc | Compounds |
US6660832B1 (en) | 1999-08-20 | 2003-12-09 | Isis Pharmaceuticals, Inc. | Macrocyclic compounds and preparation methods thereof |
US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
DE10226921A1 (de) | 2002-06-17 | 2003-12-24 | Bayer Ag | Antibakterielle Amid-Makrozyklen |
NZ544750A (en) | 2003-07-17 | 2009-06-26 | Migenix Inc | Compositions of amphomycin or aspartocin based lipopeptide antibiotic derivatives and methods of use thereof |
DE10358824A1 (de) | 2003-12-16 | 2005-07-21 | Bayer Healthcare Ag | Antibakterielle Makrozyklen mit substituiertem Biphenyl |
DE102005014247A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Antibakterielle Amid-Makrozyklen VI |
DE102005014245A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Antibakterielle Amid-Makrozyklen V |
EP2542086A4 (en) | 2010-03-01 | 2013-09-04 | Myrexis Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
KR20130028078A (ko) | 2010-03-09 | 2013-03-18 | 머크 캐나다 인크. | 베타-락탐 항박테리아제의 활성을 강화시키는 가교된 리포글리코펩티드 |
WO2011120071A1 (en) | 2010-04-01 | 2011-10-06 | The University Of Queensland | Oxytocin peptide analogues |
US9187524B2 (en) | 2010-09-15 | 2015-11-17 | The Scripps Research Institute | Broad spectrum antibiotic arylomycin analogs |
TWI642684B (zh) | 2011-05-27 | 2018-12-01 | Rqx製藥股份有限公司 | 廣效性抗生素 |
US10501493B2 (en) | 2011-05-27 | 2019-12-10 | Rqx Pharmaceuticals, Inc. | Broad spectrum antibiotics |
CN103159830B (zh) | 2011-12-15 | 2017-06-20 | 上海来益生物药物研究开发中心有限责任公司 | 脂肽类化合物 |
FR2986154B1 (fr) | 2012-01-31 | 2017-08-04 | Pierre Fabre Dermo-Cosmetique | Nouveau systeme photoprotecteur |
CN104284664A (zh) * | 2012-03-14 | 2015-01-14 | 斯克里普斯研究所 | 广谱抗生素Arylomycin类似物 |
CN103788176A (zh) | 2012-10-31 | 2014-05-14 | 上海来益生物药物研究开发中心有限责任公司 | 一种arylomycin类化合物及其制备方法和应用 |
EP2922829B1 (en) | 2012-11-21 | 2021-08-11 | RQX Pharmaceuticals, Inc. | Macrocyclic broad spectrum antibiotics |
JP6823588B2 (ja) * | 2014-05-20 | 2021-02-03 | アールキューエックス ファーマシューティカルズ,インク. | 大環状広域スペクトル抗生物質 |
ITUB20154591A1 (it) | 2015-10-12 | 2017-04-12 | Crestoptics S R L | Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini |
AU2016357926B2 (en) * | 2015-11-20 | 2021-05-27 | Genentech, Inc. | Macrocyclic broad spectrum antibiotics |
TWI725075B (zh) | 2015-11-20 | 2021-04-21 | 美商Rqx製藥公司 | 巨環廣效抗生素 |
PE20191618A1 (es) | 2017-02-15 | 2019-11-05 | Rqx Pharmaceuticals Inc | Antibioticos macrociclicos de amplio espectro |
CN117777229A (zh) | 2017-03-27 | 2024-03-29 | 豪夫迈·罗氏有限公司 | 用于制备阿龙霉素环类似物的方法 |
CN111386283A (zh) * | 2017-09-29 | 2020-07-07 | 基因泰克公司 | 肽抗菌复合物及其使用方法 |
-
2020
- 2020-05-27 AR ARP200101493A patent/AR119019A1/es unknown
- 2020-05-27 EP EP23189412.2A patent/EP4289480A3/en active Pending
- 2020-05-27 IL IL288294A patent/IL288294B/en unknown
- 2020-05-27 KR KR1020227033626A patent/KR20220137165A/ko active IP Right Grant
- 2020-05-27 LT LTEPPCT/US2020/034670T patent/LT3968983T/lt unknown
- 2020-05-27 SI SI202030269T patent/SI3968983T1/sl unknown
- 2020-05-27 RS RS20231102A patent/RS64852B1/sr unknown
- 2020-05-27 FI FIEP20814144.0T patent/FI3968983T3/fi active
- 2020-05-27 CN CN202080040183.3A patent/CN114007605B/zh active Active
- 2020-05-27 MA MA55981A patent/MA55981B1/fr unknown
- 2020-05-27 SG SG11202112920SA patent/SG11202112920SA/en unknown
- 2020-05-27 PL PL20814144.0T patent/PL3968983T3/pl unknown
- 2020-05-27 CN CN202210868626.9A patent/CN115215923A/zh active Pending
- 2020-05-27 WO PCT/US2020/034670 patent/WO2020243155A1/en active Application Filing
- 2020-05-27 HR HRP20231497TT patent/HRP20231497T1/hr unknown
- 2020-05-27 PE PE2023002563A patent/PE20240066A1/es unknown
- 2020-05-27 BR BR112021024010A patent/BR112021024010A2/pt unknown
- 2020-05-27 DK DK20814144.0T patent/DK3968983T3/da active
- 2020-05-27 EP EP20814144.0A patent/EP3968983B1/en active Active
- 2020-05-27 US US16/884,679 patent/US11208387B2/en active Active
- 2020-05-27 JP JP2021570324A patent/JP7078807B2/ja active Active
- 2020-05-27 TW TW109117701A patent/TWI815017B/zh active
- 2020-05-27 IL IL295889A patent/IL295889A/en unknown
- 2020-05-27 HU HUE20814144A patent/HUE063847T2/hu unknown
- 2020-05-27 NZ NZ783605A patent/NZ783605A/en unknown
- 2020-05-27 TW TW112136650A patent/TW202404953A/zh unknown
- 2020-05-27 MX MX2021014554A patent/MX2021014554A/es unknown
- 2020-05-27 ES ES20814144T patent/ES2961566T3/es active Active
- 2020-05-27 AU AU2020282975A patent/AU2020282975B2/en active Active
- 2020-05-27 PT PT208141440T patent/PT3968983T/pt unknown
- 2020-05-27 CR CR20210682A patent/CR20210682A/es unknown
- 2020-05-27 KR KR1020217042492A patent/KR102450071B1/ko active IP Right Grant
- 2020-05-27 CA CA3141853A patent/CA3141853A1/en active Pending
- 2020-05-27 PE PE2021001977A patent/PE20230383A1/es unknown
-
2021
- 2021-11-26 CL CL2021003153A patent/CL2021003153A1/es unknown
- 2021-11-28 SA SA521430976A patent/SA521430976B1/ar unknown
- 2021-12-17 US US17/644,861 patent/US20220135528A1/en active Pending
- 2021-12-21 CO CONC2021/0017561A patent/CO2021017561A2/es unknown
-
2022
- 2022-05-19 JP JP2022082018A patent/JP7508507B2/ja active Active
-
2023
- 2023-01-24 AU AU2023200369A patent/AU2023200369A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240066A1 (es) | Antibioticos macrociclicos de amplio espectro | |
NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
MX2023003875A (es) | Formulacion de una vacuna peptidica. | |
ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
CY1114853T1 (el) | Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσων | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
CL2007001427A1 (es) | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
CL2018000745A1 (es) | Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. | |
AR045572A1 (es) | Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato | |
CL2023001894A1 (es) | Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos | |
CL2007000945A1 (es) | Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea. | |
MX2021009439A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
BRPI0607701A2 (pt) | composto ou um sal, éster, solvato, estereoisÈmero, tautÈmero ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade antibacterialmente eficaz de um composto junto com um veìculo farmaceuticamente aceitável, e, método de preparação de um composto | |
AR114324A1 (es) | Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico | |
AR114323A1 (es) | Péptidos de la cadena b de la relaxina modificados y su uso terapéutico | |
EA202190532A1 (ru) | Ингибиторы аргиназы и способы их применения | |
CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico | |
EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием | |
BR112022001568A2 (pt) | Composto, método para preparação do composto, composição farmacêutica, e, uso do composto |